News|Articles|October 4, 2026

FAQ: What clinicians need to know about OCU410 phase 2 ArMaDa results

Author(s)Kassi Filkins, Veeral S. Sheth, MD, MBA, FACS, FASRS

Could one surgery replace years of GA injections? Phase 2 ArMaDa data suggest gene therapy OCU410 slows lesion growth.

One subretinal injection of medium-dose OCU410 (AAV5-hRORA; Ocugen) reduced geographic atrophy (GA) lesion growth by 32.3% compared with untreated controls at 12 months (nominal P = .0353) in the randomized phase 2 portion of the phase 1/2 ArMaDa trial (NCT06018558), according to data Raj K. Maturi, MD, presented at the Retina Society 2026 annual meeting in Los Angeles.^1,2